Fanconi anaemia and cancer: an intricate relationship
暂无分享,去创建一个
[1] F. Couch,et al. Exome sequencing identifies FANCM as a susceptibility gene for triple-negative breast cancer , 2014, Proceedings of the National Academy of Sciences.
[2] Mihee Lee,et al. Fanconi anemia complementation group A (FANCA) localizes to centrosomes and functions in the maintenance of centrosome integrity. , 2013, The international journal of biochemistry & cell biology.
[3] L. Shlush,et al. Clonal evolution models of tumor heterogeneity. , 2015, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.
[4] B. Vogelstein,et al. Variation in cancer risk among tissues can be explained by the number of stem cell divisions , 2015, Science.
[5] R. Schwab,et al. ATR activation and replication fork restart are defective in FANCM‐deficient cells , 2010, The EMBO journal.
[6] 中村 君代,et al. Involvement of SLX4 in interstrand cross-link repair is regulated by the Fanconi anemia pathway , 2012 .
[7] P. Fei,et al. Mutated Fanconi anemia pathway in non-Fanconi anemia cancers , 2015, Oncotarget.
[8] G. Gill,et al. Noncovalent interactions with SUMO and ubiquitin orchestrate distinct functions of the SLX4 complex in genome maintenance. , 2015, Molecular cell.
[9] Marianne Berwick,et al. A 20-year perspective on the International Fanconi Anemia Registry (IFAR). , 2003, Blood.
[10] B. Alter. Fanconi anemia and the development of leukemia. , 2014, Best practice & research. Clinical haematology.
[11] Q. Waisfisz,et al. Hypermethylation of the FANCC and FANCL Promoter Regions in Sporadic Acute Leukaemia , 2008, Cellular oncology : the official journal of the International Society for Cellular Oncology.
[12] Franca Fraternali,et al. Mutation of the RAD51C gene in a Fanconi anemia–like disorder , 2010, Nature Genetics.
[13] D. Petersen,et al. An overview of the chemistry and biology of reactive aldehydes. , 2013, Free radical biology & medicine.
[14] A. D’Andrea,et al. ATR couples FANCD2 monoubiquitination to the DNA-damage response. , 2004, Genes & development.
[15] S. Asano,et al. The IVS4 + 4 A to T mutation of the fanconi anemia gene FANCC is not associated with a severe phenotype in Japanese patients. , 2000, Blood.
[16] L. Hood,et al. A novel Fanconi anaemia subtype associated with a dominant-negative mutation in RAD51 , 2015, Nature Communications.
[17] D. Schindler,et al. Distinct functional roles for the two SLX4 ubiquitin-binding UBZ domains mutated in Fanconi anemia , 2014, Journal of Cell Science.
[18] P. Fuchs,et al. Hyperbaric oxygen treatment decreases inflammation and mechanical hypersensitivity in an animal model of inflammatory pain , 2006, Brain Research.
[19] C. Lewis,et al. Association of complementation group and mutation type with clinical outcome in fanconi anemia. European Fanconi Anemia Research Group. , 2000, Blood.
[20] A. D’Andrea,et al. Chk1-Mediated Phosphorylation of FANCE Is Required for the Fanconi Anemia/BRCA Pathway , 2007, Molecular and Cellular Biology.
[21] F. Rosselli,et al. Fanconi anemia C gene product regulates expression of genes involved in differentiation and inflammation , 2004, Oncogene.
[22] P. Rosenberg,et al. Frequency and natural history of inherited bone marrow failure syndromes: the Israeli Inherited Bone Marrow Failure Registry , 2008, Haematologica.
[23] D. Matei,et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: A preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial , 2014 .
[24] F. Couch,et al. Germ line Fanconi anemia complementation group C mutations and pancreatic cancer. , 2005, Cancer research.
[25] A. D’Andrea,et al. Phosphorylation of FANCD2 on Two Novel Sites Is Required for Mitomycin C Resistance , 2006, Molecular and Cellular Biology.
[26] F. Couch,et al. Control of BRCA2 cellular and clinical functions by a nuclear partner, PALB2. , 2006, Molecular cell.
[27] S. Jackson,et al. ATM, ATR, and DNA-PK: The Trinity at the Heart of the DNA Damage Response. , 2017, Molecular cell.
[28] Neil J Ganem,et al. DNA breaks and chromosome pulverization from errors in mitosis , 2012, Nature.
[29] M. Bakhanashvili,et al. Oxidative stress causes telomere damage in Fanconi anaemia cells – a possible predisposition for malignant transformation , 2008, British journal of haematology.
[30] A. D’Andrea,et al. FANCD2 activates transcription of TAp63 and suppresses tumorigenesis. , 2013, Molecular cell.
[31] S. Ganesan,et al. Interaction of the Fanconi anemia proteins and BRCA1 in a common pathway. , 2001, Molecular cell.
[32] S. Miyano,et al. Variant ALDH2 is associated with accelerated progression of bone marrow failure in Japanese Fanconi anemia patients. , 2013, Blood.
[33] M. O'Dwyer,et al. Interferon-gamma-induced apoptotic responses of Fanconi anemia group C hematopoietic progenitor cells involve caspase 8-dependent activation of caspase 3 family members. , 2000, Blood.
[34] David Pellman,et al. Causes and consequences of aneuploidy in cancer , 2012, Nature Reviews Genetics.
[35] Chunaram Choudhary,et al. Ubiquitin-SUMO Circuitry Controls Activated Fanconi Anemia ID Complex Dosage in Response to DNA Damage , 2015, Molecular cell.
[36] Jakub Tolar,et al. Germline mutations in BRCA2: shared genetic susceptibility to breast cancer, early onset leukemia, and Fanconi anemia. , 2004, Blood.
[37] P. Andreassen,et al. The FA pathway counteracts oxidative stress through selective protection of antioxidant defense gene promoters. , 2012, Blood.
[38] R. Hruban,et al. Fanconi anemia gene mutations in young-onset pancreatic cancer. , 2003, Cancer research.
[39] René Bernards,et al. The deubiquitinating enzyme USP1 regulates the Fanconi anemia pathway. , 2005, Molecular cell.
[40] S. Fagerlie,et al. Immune defects in Fanconi anemia. , 2006, Critical reviews in immunology.
[41] J. Opitz,et al. Fanconi anemia: Another disease of unusually high prevalence in the Afrikaans population of South africa , 1987, American journal of medical genetics.
[42] P. Rosenberg,et al. Risk of head and neck squamous cell cancer and death in patients with Fanconi anemia who did and did not receive transplants. , 2005, Blood.
[43] P. Rosenberg,et al. Clinical and molecular features associated with biallelic mutations in FANCD1/BRCA2 , 2006, Journal of Medical Genetics.
[44] J. Soulier,et al. Fanconi anemia and solid malignancies in childhood: A national retrospective study , 2015, Pediatric blood & cancer.
[45] Gordon Royle,et al. Inactivation of the Fanconi anemia group C gene augments interferon-gamma-induced apoptotic responses in hematopoietic cells. , 1997, Blood.
[46] J. Kutok,et al. Hematopoietic Stem Cell Defects in Mice with Deficiency of Fancd2 or Usp1 , 2010, Stem cells.
[47] J. Surrallés,et al. Fanconi anemia: a model disease for studies on human genetics and advanced therapeutics. , 2015, Current opinion in genetics & development.
[48] A. D’Andrea,et al. Association of biallelic BRCA2/FANCD1 mutations with spontaneous chromosomal instability and solid tumors of childhood. , 2004, Blood.
[49] Alan Ashworth,et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy , 2005, Nature.
[50] W. Han,et al. BRCA2 fine-tunes the spindle assembly checkpoint through reinforcement of BubR1 acetylation. , 2012, Developmental cell.
[51] Anindya Dutta,et al. UBE2T is the E2 in the Fanconi anemia pathway and undergoes negative autoregulation. , 2006, Molecular cell.
[52] C. Lewis,et al. A common Fanconi anemia mutation in black populations of sub-Saharan Africa. , 2005, Blood.
[53] T. Nakajima,et al. Two common founder mutations of the fanconi anemia group g gene FANCG/XRCC9 in the Japanese population , 2003, Human mutation.
[54] B. Bay,et al. Evidence of mitochondrial dysfunction and impaired ROS detoxifying machinery in Fanconi Anemia cells , 2014, Oncogene.
[55] D. Huo,et al. SUMO Modification Regulates BLM and RAD51 Interaction at Damaged Replication Forks , 2009, PLoS biology.
[56] D. Goldman. Aldehyde Dehydrogenase Deficiency as Cause of Facial Flushing Reaction to Alcohol in Japanese , 1995, Alcohol health and research world.
[57] M. Grompe,et al. Fancd2-/- mice have hematopoietic defects that can be partially corrected by resveratrol. , 2010, Blood.
[58] Bo Xu,et al. Convergence of the Fanconi Anemia and Ataxia Telangiectasia Signaling Pathways , 2002, Cell.
[59] J. Taube,et al. Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy , 2016, Nature Reviews Cancer.
[60] J. V. van Deursen,et al. Centrosome dynamics as a source of chromosomal instability. , 2015, Trends in cell biology.
[61] I. Vořechovský,et al. Deletion and reduced expression of the Fanconi anemia FANCA gene in sporadic acute myeloid leukemia , 2004, Leukemia.
[62] S. Venitt,et al. DNA and protein adducts in human tissues resulting from exposure to tobacco smoke , 2012, International journal of cancer.
[63] Min Huang,et al. Inactivation of murine Usp1 results in genomic instability and a Fanconi anemia phenotype. , 2009, Developmental cell.
[64] H. Sies,et al. Oxidative stress: a concept in redox biology and medicine , 2015, Redox biology.
[65] R. Gibbons,et al. The Fanconi Anemia Pathway Maintains Genome Stability by Coordinating Replication and Transcription , 2015, Molecular cell.
[66] S. Spunt,et al. The clinical phenotype of children with Fanconi anemia caused by biallelic FANCD1/BRCA2 mutations , 2012, Pediatric blood & cancer.
[67] D. Schindler,et al. Androgen therapy in Fanconi anemia: A retrospective analysis of 30 years in Germany , 2016, Pediatric hematology and oncology.
[68] B. Delaval,et al. Loss of centrosome integrity induces p38—p53—p21-dependent G1—S arrest , 2007, Nature Cell Biology.
[69] K. J. Patel,et al. Endogenous Formaldehyde Is a Hematopoietic Stem Cell Genotoxin and Metabolic Carcinogen , 2015, Molecular cell.
[70] T. Kühne,et al. Fanconi Anemia: Overview of the Disease and the Role of Hematopoietic Transplantation , 2015, Journal of pediatric hematology/oncology.
[71] A. Utani,et al. Malfunction of nuclease ERCC1-XPF results in diverse clinical manifestations and causes Cockayne syndrome, xeroderma pigmentosum, and Fanconi anemia. , 2013, American journal of human genetics.
[72] Hans Joenje,et al. Biallelic Inactivation of BRCA2 in Fanconi Anemia , 2002, Science.
[73] K. Mimori,et al. FANCD2 mRNA Overexpression is a Bona Fide Indicator of Lymph Node Metastasis in Human Colorectal Cancer , 2010, Annals of Surgical Oncology.
[74] Y. Miki,et al. BRCA2 and nucleophosmin coregulate centrosome amplification and form a complex with the Rho effector kinase ROCK2. , 2011, Cancer research.
[75] Hong Wu,et al. A distinct replication fork protection pathway connects Fanconi anemia tumor suppressors to RAD51-BRCA1/2. , 2012, Cancer cell.
[76] S. Elledge,et al. Mechanism of DNA interstrand cross-link processing by repair nuclease FAN1 , 2014, Science.
[77] K. Kraemer,et al. Forty Years of Research on Xeroderma Pigmentosum at the US National Institutes of Health , 2015, Photochemistry and photobiology.
[78] L. Beretta,et al. Multiple phosphorylation of stathmin. Identification of four sites phosphorylated in intact cells and in vitro by cyclic AMP-dependent protein kinase and p34cdc2. , 1993, The Journal of biological chemistry.
[79] H. Joenje,et al. Oxygen-dependence of chromosomal aberrations in Fanconi's anaemia , 1981, Nature.
[80] Yousef Ahmed Fouad,et al. Revisiting the hallmarks of cancer. , 2017, American journal of cancer research.
[81] C. Bertolotto,et al. FANCD2 functions as a critical factor downstream of MiTF to maintain the proliferation and survival of melanoma cells , 2016, Scientific Reports.
[82] Q. Waisfisz,et al. Aberrant Fanconi anaemia protein profiles in acute myeloid leukaemia cells , 2000, British journal of haematology.
[83] David A. Williams,et al. TNF-α induces leukemic clonal evolution ex vivo in Fanconi anemia group C murine stem cells , 2007 .
[84] G. Nalepa,et al. FANCA safeguards interphase and mitosis during hematopoiesis in vivo. , 2015, Experimental hematology.
[85] Bhuvanesh Singh,et al. Downregulation of Fanconi Anemia Genes in Sporadic Head and Neck Squamous Cell Carcinoma , 2007, ORL.
[86] P. Rosenberg,et al. How high are carrier frequencies of rare recessive syndromes? Contemporary estimates for Fanconi Anemia in the United States and Israel , 2011, American journal of medical genetics. Part A.
[87] M. Malumbres,et al. A centrosomal route for cancer genome instability , 2014, Nature Cell Biology.
[88] E. Friedman,et al. The risk for developing cancer in Israeli ATM, BLM, and FANCC heterozygous mutation carriers. , 2016, Cancer genetics.
[89] N. Ellis,et al. The Bloom's syndrome gene product is homologous to RecQ helicases , 1995, Cell.
[90] W. Vainchenker,et al. Defective endomitosis during megakaryopoiesis leads to thrombocytopenia in Fanca-/- mice. , 2014, Blood.
[91] S. Elowe,et al. The Fanconi Anemia C Protein Binds to and Regulates Stathmin-1 Phosphorylation , 2015, PloS one.
[92] F. Couch,et al. Biallelic deleterious BRCA1 mutations in a woman with early-onset ovarian cancer. , 2013, Cancer discovery.
[93] I. Hickson,et al. Replication stress induces sister-chromatid bridging at fragile site loci in mitosis , 2009, Nature Cell Biology.
[94] A. D’Andrea,et al. FANCD2 Maintains Fork Stability in BRCA1/2-Deficient Tumors and Promotes Alternative End-Joining DNA Repair. , 2016, Cell reports.
[95] D. Schindler,et al. Delayed diagnosis and complications of Fanconi anaemia at advanced age – a paradigm , 2006, British journal of haematology.
[96] A. Look,et al. CHK1 inhibition as a strategy for targeting fanconi anemia (FA) DNA repair pathway deficient tumors , 2009, Molecular Cancer.
[97] L. G. Korkina,et al. In vitro hypersensitivity to oxygen of Fanconi anemia (FA) cells is linked to ex vivo evidence for oxidative stress in FA homozygotes and heterozygotes. , 1997, Blood.
[98] C. Mathew,et al. Molecular and genealogical evidence for a founder effect in Fanconi anemia families of the Afrikaner population of South Africa , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[99] M. Grompe,et al. Inactivation of the Fanconi anemia group C gene augments interferon-gamma-induced apoptotic responses in hematopoietic cells. , 1997, Blood.
[100] C. Mathew,et al. Disruption of the Fanconi anemia–BRCA pathway in cisplatin-sensitive ovarian tumors , 2003, Nature Medicine.
[101] A. D’Andrea,et al. The Fanconi anaemia pathway: new players and new functions , 2016, Nature Reviews Molecular Cell Biology.
[102] B. Alter,et al. Androgens and liver tumors: Fanconi's anemia and non‐Fanconi's conditions , 2004, American journal of hematology.
[103] A. Klyosov,et al. Possible role of liver cytosolic and mitochondrial aldehyde dehydrogenases in acetaldehyde metabolism. , 1996, Biochemistry.
[104] B. Dunn,et al. Future directions in cancer prevention , 2012, Nature Reviews Cancer.
[105] C. Mathew,et al. Bi‐allelic silencing of the Fanconi anaemia gene FANCF in acute myeloid leukaemia , 2003, British journal of haematology.
[106] A. D’Andrea,et al. Mouse models of Fanconi anemia. , 2009, Mutation research.
[107] R. Kaaks,et al. Lifestyle and Cancer Risk , 2015, Cancer journal.
[108] N. de Wind,et al. Maternal Aldehyde Elimination during Pregnancy Preserves the Fetal Genome , 2014, Molecular cell.
[109] David M. Wilson,et al. Direct and indirect roles of RECQL4 in modulating base excision repair capacity. , 2009, Human molecular genetics.
[110] S. Elledge,et al. Identification of the FANCI Protein, a Monoubiquitinated FANCD2 Paralog Required for DNA Repair , 2007, Cell.
[111] K. Straif,et al. Carcinogenicity of alcoholic beverages. , 2007, The Lancet. Oncology.
[112] A. Auerbach,et al. Fanconi anemia and its diagnosis. , 2009, Mutation research.
[113] D. Schindler,et al. SLX4, a coordinator of structure-specific endonucleases, is mutated in a new Fanconi anemia subtype , 2011, Nature Genetics.
[114] C. Mathew,et al. A common founder mutation in FANCA underlies the world highest prevalence of Fanconi anemia in Gypsy families from Spain , 2004 .
[115] Benjamin E. Gross,et al. Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal , 2013, Science Signaling.
[116] W. Du,et al. TNF-α signaling in Fanconi anemia. , 2014, Blood cells, molecules & diseases.
[117] N. Ellis,et al. Bloom's Syndrome: Clinical Spectrum, Molecular Pathogenesis, and Cancer Predisposition , 2016, Molecular Syndromology.
[118] M. Malumbres,et al. Fueling the Cell Division Cycle. , 2017, Trends in cell biology.
[119] Weidong Wang,et al. Fanconi Anemia Proteins Are Required To Prevent Accumulation of Replication-Associated DNA Double-Strand Breaks , 2006, Molecular and Cellular Biology.
[120] G. Kupfer,et al. Several tetratricopeptide repeat (TPR) motifs of FANCG are required for assembly of the BRCA2/D1-D2-G-X3 complex, FANCD2 monoubiquitylation and phleomycin resistance. , 2010, Mutation research.
[121] Giovanni Parmigiani,et al. Meta-analysis of BRCA1 and BRCA2 penetrance. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[122] J. Satagopan,et al. Genetic heterogeneity among Fanconi anemia heterozygotes and risk of cancer. , 2007, Cancer research.
[123] S. Lobitz,et al. Guido Fanconi (1892–1979): a jack of all trades , 2006, Nature Reviews Cancer.
[124] Z. Hořejší,et al. Preventing nonhomologous end joining suppresses DNA repair defects of Fanconi anemia. , 2010, Molecular cell.
[125] V. Bohr,et al. RECQL4 in genomic instability and aging. , 2012, Trends in genetics : TIG.
[126] A. Ghavamzadeh,et al. Calcitriol for Oral Mucositis Prevention in Patients With Fanconi Anemia Undergoing Hematopoietic SCT: A Double-Blind, Randomized, Placebo-Controlled Trial , 2016, American journal of therapeutics.
[127] A. Venkitaraman,et al. Abnormal Cytokinesis in Cells Deficient in the Breast Cancer Susceptibility Protein BRCA2 , 2004, Science.
[128] Hongmin Wang,et al. FancJ regulates interstrand crosslinker induced centrosome amplification through the activation of polo-like kinase 1 , 2013, Biology Open.
[129] A. Cox,et al. FANCD2 re-expression is associated with glioma grade and chemical inhibition of the Fanconi Anaemia pathway sensitises gliomas to chemotherapeutic agents , 2014, Oncotarget.
[130] S. Plon,et al. Defective mitochondrial peroxiredoxin-3 results in sensitivity to oxidative stress in Fanconi anemia , 2006, The Journal of cell biology.
[131] M. Grompe,et al. Evaluation of resveratrol and N‐acetylcysteine for cancer chemoprevention in a Fanconi anemia murine model , 2014, Pediatric blood & cancer.
[132] I. Tomlinson,et al. The mini-driver model of polygenic cancer evolution , 2015, Nature Reviews Cancer.
[133] J. Shah,et al. High incidence of head and neck squamous cell carcinoma in patients with Fanconi anemia. , 2003, Archives of otolaryngology--head & neck surgery.
[134] T. Ludwig,et al. BRCA1 functions independently of homologous recombination in DNA interstrand crosslink repair. , 2012, Molecular cell.
[135] Chantal Stoepker,et al. Mutations in ERCC4, encoding the DNA-repair endonuclease XPF, cause Fanconi anemia. , 2013, American journal of human genetics.
[136] Anton Simeonov,et al. A selective USP1-UAF1 inhibitor links deubiquitination to DNA damage responses. , 2014, Nature chemical biology.
[137] R. Tothill,et al. Exome Sequencing Identifies Rare Deleterious Mutations in DNA Repair Genes FANCC and BLM as Potential Breast Cancer Susceptibility Alleles , 2012, PLoS genetics.
[138] G. Nalepa,et al. Evaluation and Management of Chronic Pancytopenia , 2016, Pediatrics in Review.
[139] P. Jeggo,et al. Identification of a nonsense mutation in the carboxyl-terminal region of DNA-dependent protein kinase catalytic subunit in the scid mouse. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[140] J. Thigpen. Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer , 2012 .
[141] Julian Peto,et al. Identification of the breast cancer susceptibility gene BRCA2 , 1996, Nature.
[142] J. Soulier,et al. Biallelic inactivation of REV7 is associated with Fanconi anemia. , 2016, The Journal of clinical investigation.
[143] J. Garber,et al. RNF4-mediated polyubiquitination regulates the Fanconi anemia/BRCA pathway. , 2015, The Journal of clinical investigation.
[144] C. Bishop,et al. A novel ubiquitin ligase is deficient in Fanconi anemia , 2003, Nature Genetics.
[145] B. Karlan,et al. Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[146] Stephen C. West,et al. DNA interstrand crosslink repair and cancer , 2011, Nature Reviews Cancer.
[147] F. Sigaux,et al. Myelodysplasia and leukemia of Fanconi anemia are associated with a specific pattern of genomic abnormalities that includes cryptic RUNX1/AML1 lesions. , 2011, Blood.
[148] Val Gebski,et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. , 2017, The Lancet. Oncology.
[149] Akiko Shimamura,et al. Fanconi anemia pathway-deficient tumor cells are hypersensitive to inhibition of ataxia telangiectasia mutated. , 2007, The Journal of clinical investigation.
[150] P. Sicinski,et al. Cell cycle proteins as promising targets in cancer therapy , 2017, Nature Reviews Cancer.
[151] J. Ott,et al. The BRCA1-interacting helicase BRIP1 is deficient in Fanconi anemia , 2005, Nature Genetics.
[152] J Wade Harper,et al. A genetic screen identifies FAN1, a Fanconi anemia-associated nuclease necessary for DNA interstrand crosslink repair. , 2010, Molecular cell.
[153] S. West,et al. Aberrant chromosome morphology in human cells defective for Holliday junction resolution , 2011, Nature.
[154] Martin Kircher,et al. Biallelic mutations in BRCA1 cause a new Fanconi anemia subtype. , 2015, Cancer discovery.
[155] N. Bec,et al. FANCD2 binds MCM proteins and controls replisome function upon activation of s phase checkpoint signaling. , 2013, Molecular cell.
[156] Alan Ashworth,et al. PARP inhibitors: Synthetic lethality in the clinic , 2017, Science.
[157] M. Saadatzadeh,et al. Oxidant Hypersensitivity of Fanconi Anemia Type C-deficient Cells Is Dependent on a Redox-regulated Apoptotic Pathway* , 2004, Journal of Biological Chemistry.
[158] C. Bertolotto,et al. Essential role of microphthalmia transcription factor for DNA replication, mitosis and genomic stability in melanoma , 2011, Oncogene.
[159] D. Pellman,et al. Cytokinesis failure occurs in Fanconi anemia pathway-deficient murine and human bone marrow hematopoietic cells. , 2010, The Journal of clinical investigation.
[160] S. Cross,et al. No evidence that protein truncating variants in BRIP1 are associated with breast cancer risk: implications for gene panel testing , 2016, Journal of Medical Genetics.
[161] Andrew P. Feinberg,et al. Epigenetic modulators, modifiers and mediators in cancer aetiology and progression , 2016, Nature Reviews Genetics.
[162] P. Cohen,et al. p53-Driven apoptosis limits centrosome amplification and genomic instability downstream of NPM1 phosphorylation , 2008, Nature Cell Biology.
[163] M. Barbacid,et al. Cell cycle, CDKs and cancer: a changing paradigm , 2009, Nature Reviews Cancer.
[164] J. Soulier,et al. Bone marrow failure in Fanconi anemia is triggered by an exacerbated p53/p21 DNA damage response that impairs hematopoietic stem and progenitor cells. , 2012, Cell stem cell.
[165] S. Miyano,et al. Mutations in the gene encoding the E2 conjugating enzyme UBE2T cause Fanconi anemia. , 2015, American journal of human genetics.
[166] M. Buchwald,et al. Multiple inhibitory cytokines induce deregulated progenitor growth and apoptosis in hematopoietic cells from Fac-/- mice. , 1998, Blood.
[167] E. Jabs,et al. Revisiting the craniosynostosis-radial ray hypoplasia association: Baller-Gerold syndrome caused by mutations in the RECQL4 gene , 2005, Journal of Medical Genetics.
[168] J. Walter,et al. Mechanism of RAD51-Dependent DNA Interstrand Cross-Link Repair , 2011, Science.
[169] B. Alter,et al. Pathophysiology and management of inherited bone marrow failure syndromes. , 2010, Blood reviews.
[170] Y. Miki,et al. BRCA2 phosphorylated by PLK1 moves to the midbody to regulate cytokinesis mediated by nonmuscle myosin IIC. , 2014, Cancer research.
[171] David Pellman,et al. A Mechanism Linking Extra Centrosomes to Chromosomal Instability , 2009, Nature.
[172] V. Pankratz,et al. BRCA2 localization to the midbody by filamin A regulates cep55 signaling and completion of cytokinesis. , 2012, Developmental cell.
[173] K. J. Patel,et al. Genotoxic consequences of endogenous aldehydes on mouse haematopoietic stem cell function , 2012, Nature.
[174] Y. Hannun,et al. Substantial contribution of extrinsic risk factors to cancer development , 2015, Nature.
[175] Liang Zhao,et al. FDA Approval Summary: Olaparib Monotherapy in Patients with Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer Treated with Three or More Lines of Chemotherapy , 2015, Clinical Cancer Research.
[176] G. Kupfer,et al. Fanconi anemia complementation group FANCD2 protein serine 331 phosphorylation is important for fanconi anemia pathway function and BRCA2 interaction. , 2009, Cancer research.
[177] J. Soulier,et al. Spontaneous abrogation of the G₂DNA damage checkpoint has clinical benefits but promotes leukemogenesis in Fanconi anemia patients. , 2011, The Journal of clinical investigation.
[178] Kornelia Neveling,et al. Genotype-phenotype correlations in Fanconi anemia. , 2009, Mutation research.
[179] A. Kauffmann,et al. High expression of DNA repair pathways is associated with metastasis in melanoma patients , 2008, Oncogene.
[180] kConFab investigators,et al. No evidence that protein truncating variants in BRIP1 are associated with breast cancer risk: implications for gene panel testing , 2016 .
[181] C. Mathew,et al. Biallelic mutations in PALB2 cause Fanconi anemia subtype FA-N and predispose to childhood cancer , 2007, Nature Genetics.
[182] A. Ashworth,et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. , 2009, The New England journal of medicine.
[183] S. Elledge,et al. FANCI phosphorylation functions as a molecular switch to turn on the Fanconi anemia pathway , 2008, Nature Structural &Molecular Biology.
[184] G. Vance,et al. Genetic disruption of both Fancc and Fancg in mice recapitulates the hematopoietic manifestations of Fanconi anemia. , 2010, Blood.
[185] S. Gabriel,et al. Deficiency of UBE2T, the E2 Ubiquitin Ligase Necessary for FANCD2 and FANCI Ubiquitination, Causes FA-T Subtype of Fanconi Anemia. , 2015, Cell reports.
[186] R. Saffery,et al. Biallelic FANCD1/BRCA2 mutations predisposing to glioblastoma multiforme with multiple oncogenic amplifications. , 2016, Cancer genetics.
[187] Yunje Cho,et al. Crystal structure of a Fanconi anemia-associated nuclease homolog bound to 5′ flap DNA: basis of interstrand cross-link repair by FAN1 , 2014, Genes & development.
[188] T. Ben Othman,et al. Bone marrow transplantation from matched related donors for patients with Fanconi anemia using low‐dose busulfan and cyclophosphamide as conditioning , 2006, Pediatric blood & cancer.
[189] Manikandan Paramasivam,et al. ATR-dependent phosphorylation of FANCM at serine 1045 is essential for FANCM functions. , 2013, Cancer research.
[190] Ashish Ranjan Sharma,et al. Application of Bioactive Quercetin in Oncotherapy: From Nutrition to Nanomedicine , 2016, Molecules.
[191] David A. Williams,et al. Exit from dormancy provokes DNA-damage-induced attrition in haematopoietic stem cells , 2015, Nature.
[192] A. D’Andrea,et al. A novel diagnostic screen for defects in the Fanconi anemia pathway. , 2002, Blood.
[193] J. Mi,et al. Phosphorylation of Fanconi Anemia (FA) Complementation Group G Protein, FANCG, at Serine 7 Is Important for Function of the FA Pathway* , 2004, Journal of Biological Chemistry.
[194] P. J. Brooks,et al. Acetaldehyde and the genome: Beyond nuclear DNA adducts and carcinogenesis , 2014, Environmental and molecular mutagenesis.
[195] H. Broxmeyer,et al. Fanconi anemia type C and p53 cooperate in apoptosis and tumorigenesis. , 2003, Blood.
[196] Y. Kong,et al. Loss of BubR1 acetylation causes defects in spindle assembly checkpoint signaling and promotes tumor formation , 2013, The Journal of cell biology.
[197] S. E. Stanley,et al. The short and long telomere syndromes: paired paradigms for molecular medicine. , 2015, Current opinion in genetics & development.
[198] A. D’Andrea,et al. The Fanconi anemia polypeptide, FAC, binds to the cyclin-dependent kinase, cdc2. , 1997, Blood.
[199] Soo Hyun Lee,et al. Acute myeloid leukemia with complex hypodiploidy and loss of heterozygosity of 17p in a boy with Fanconi anemia. , 2011, Annals of clinical and laboratory science.
[200] N. Ellis,et al. Transfection of BLM into cultured bloom syndrome cells reduces the sister-chromatid exchange rate toward normal. , 1999, American journal of human genetics.
[201] T. Mak,et al. Modulation of oxidative stress as an anticancer strategy , 2013, Nature Reviews Drug Discovery.
[202] F. Pallardó,et al. Bone marrow cell transcripts from Fanconi anaemia patients reveal in vivo alterations in mitochondrial, redox and DNA repair pathways , 2013, European journal of haematology.
[203] P. Rosenberg,et al. Malignancies and survival patterns in the National Cancer Institute inherited bone marrow failure syndromes cohort study , 2010, British journal of haematology.
[204] M. Sivasubramaniam,et al. Ku70 Corrupts DNA Repair in the Absence of the Fanconi Anemia Pathway , 2010, Science.
[205] Sue Biggins,et al. Signalling dynamics in the spindle checkpoint response , 2014, Nature Reviews Molecular Cell Biology.
[206] D. Compton,et al. Regulation of kinetochore–microtubule attachments through homeostatic control during mitosis , 2014, Nature Reviews Molecular Cell Biology.
[207] J. Diffley,et al. Separate roles for the DNA damage checkpoint protein kinases in stabilizing DNA replication forks. , 2008, Genes & development.
[208] P. Andreassen,et al. Elucidation of the Fanconi Anemia Protein Network in Meiosis and Its Function in the Regulation of Histone Modifications , 2016, Cell reports.
[209] N. Lindor,et al. Therapy‐related myelodysplasia in a patient with Rothmund–Thomson syndrome , 2011, European journal of haematology.
[210] A. Auerbach,et al. Mutations of the SLX4 gene in Fanconi anemia , 2011, Nature Genetics.
[211] F. Rosselli,et al. The FANC pathway and BLM collaborate during mitosis to prevent micro-nucleation and chromosome abnormalities , 2009, Nature Cell Biology.
[212] E. Zackai,et al. Association between osteosarcoma and deleterious mutations in the RECQL4 gene in Rothmund-Thomson syndrome. , 2003, Journal of the National Cancer Institute.
[213] U. McDermott,et al. FANCD2 limits replication stress and genome instability in cells lacking BRCA2 , 2016, Nature Structural &Molecular Biology.
[214] ALDH2 polymorphism and alcohol-related cancers in Asians: a public health perspective , 2017, Journal of Biomedical Science.
[215] F. Rosselli,et al. The SLX4 complex is a SUMO E3 ligase that impacts on replication stress outcome and genome stability. , 2015, Molecular cell.
[216] K. Klooster,et al. Germline Mutations in Predisposition Genes in Pediatric Cancer , 2016 .
[217] G. Nalepa,et al. Leukemia and chromosomal instability in aged Fancc-/- mice. , 2016, Experimental hematology.
[218] Thomas Helleday,et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase , 2007, Nature.
[219] A. D’Andrea,et al. Chemosensitization to cisplatin by inhibitors of the Fanconi anemia/BRCA pathway , 2006, Molecular Cancer Therapeutics.
[220] Robert W. Miller,et al. Mutations in RECQL4 cause a subset of cases of Rothmund-Thomson syndrome , 1999, Nature Genetics.
[221] K. J. Patel,et al. Fancd2 counteracts the toxic effects of naturally produced aldehydes in mice , 2011, Nature.
[222] C. Mathew,et al. The DNA helicase BRIP1 is defective in Fanconi anemia complementation group J , 2005, Nature Genetics.
[223] A. Helmrich,et al. Collisions between replication and transcription complexes cause common fragile site instability at the longest human genes. , 2011, Molecular cell.
[224] F. Rosselli,et al. Impaired TIP60-mediated H4K16 acetylation accounts for the aberrant chromatin accumulation of 53BP1 and RAP80 in Fanconi anemia pathway-deficient cells , 2015, Nucleic acids research.
[225] M. Grompe,et al. Fancd2 functions in a double strand break repair pathway that is distinct from non-homologous end joining. , 2005, Human molecular genetics.
[226] Matthew N Davies,et al. Dissecting cancer evolution at the macro-heterogeneity and micro-heterogeneity scale , 2015, Current opinion in genetics & development.
[227] M. Buchwald,et al. Defective hematopoiesis and hepatic steatosis in mice with combined deficiencies of the genes encoding Fancc and Cu/Zn superoxide dismutase. , 2001, Blood.
[228] R. Hennekam,et al. The mutation spectrum in RECQL4 diseases , 2009, European Journal of Human Genetics.
[229] G. Kupfer,et al. ATR-dependent phosphorylation of FANCA on serine 1449 after DNA damage is important for FA pathway function. , 2009, Blood.
[230] Sikandar G. Khan,et al. Cancer and neurologic degeneration in xeroderma pigmentosum: long term follow-up characterises the role of DNA repair , 2010, Journal of Medical Genetics.
[231] Ayala Hubert,et al. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[232] S. Gabriel,et al. A Dominant Mutation in Human RAD51 Reveals Its Function in DNA Interstrand Crosslink Repair Independent of Homologous Recombination. , 2015, Molecular cell.
[233] H. Tanke,et al. BRCA2 Heterozygosity Delays Cytokinesis in Primary Human Fibroblasts , 2009, Cellular oncology : the official journal of the International Society for Cellular Oncology.
[234] W. El-Deiry,et al. p21WAF1 and tumourigenesis: 20 years after , 2013, Current opinion in oncology.
[235] David Goldman,et al. The Alcohol Flushing Response: An Unrecognized Risk Factor for Esophageal Cancer from Alcohol Consumption , 2009, PLoS medicine.
[236] J. Jónasson,et al. Tetraploidy in BRCA2 breast tumours. , 2012, European journal of cancer.
[237] P. Andreassen,et al. FANCB is essential in the male germline and regulates H3K9 methylation on the sex chromosomes during meiosis. , 2015, Human molecular genetics.
[238] A. Jankowska,et al. AluY-mediated germline deletion, duplication and somatic stem cell reversion in UBE2T defines a new subtype of Fanconi anemia , 2015, Human molecular genetics.
[239] H. Walden,et al. The structure of FANCL, the catalytic subunit of the Fanconi Anemia core complex , 2010, Nature Structural &Molecular Biology.
[240] M. Krem,et al. Mechanisms and clinical applications of chromosomal instability in lymphoid malignancy , 2015, British journal of haematology.
[241] D. Sahani,et al. Case records of the Massachusetts General Hospital. Case 13-2006. A 50-year-old man with a painful bone mass and lesions in the liver. , 2006, The New England journal of medicine.
[242] G. Nalepa,et al. Fanconi anemia signaling network regulates the spindle assembly checkpoint. , 2013, The Journal of clinical investigation.
[243] B. Alter,et al. VACTERL-H Association and Fanconi Anemia , 2012, Molecular Syndromology.
[244] J. Heredia,et al. Flavonoids as Cytokine Modulators: A Possible Therapy for Inflammation-Related Diseases , 2016, International journal of molecular sciences.
[245] M. Roizen,et al. Hallmarks of Cancer: The Next Generation , 2012 .
[246] J. Hopper,et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. , 2003, American journal of human genetics.
[247] Chao Yang,et al. Monoketone analogs of curcumin, a new class of Fanconi anemia pathway inhibitors , 2009, Molecular Cancer.
[248] J. Rommens,et al. Draft consensus guidelines for diagnosis and treatment of Shwachman‐Diamond syndrome , 2011, Annals of the New York Academy of Sciences.
[249] F. Rosselli,et al. The DNA crosslink‐induced S‐phase checkpoint depends on ATR–CHK1 and ATR–NBS1–FANCD2 pathways , 2004, The EMBO journal.